Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways to treat autoimmune and inflammatory diseases. The company's pipeline includes three initial assets: ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter that completed Phase 2b testing for rheumatoid arthritis; and ANB101, a BDCA2 modulator in Phase 1a development. Headquartered in San Diego, California, First Tracks Biotherapeutics is a recently established independent company focused on advancing innovative antibody-based therapies to address significant unmet needs in autoimmune and inflammatory disease treatment. The company operates as a pure-play biopharmaceutical developer, concentrating exclusively on its targeted therapeutic programs.
$46.13
$0.62 (-1.33%)
EOD Aug 12, 2026
ROIC dropped from -21.88% to -34.26%, capital efficiency is deteriorating. Negative free cash flow of -$126M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$164M
▼ -54.2% YoY
Op. Margin
—
ROIC
-34.26%
▼ -12.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$126M
▼ -34.5% YoY
Op. Cash Flow (TTM)
-$126M
▼ -35.3% YoY
Net Debt
-$369M
Net Cash Position
Cash & Equiv.
$385M
Continue Research
First Tracks Biotherapeutics (TRAX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, First Tracks Biotherapeutics scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
First Tracks Biotherapeutics scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -34.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh TRAX's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.